Publications by authors named "R J Bisoendial"

Background: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are inflammatory diseases that often affect the wrist and, when affected, can lead to impaired wrist function and progressive joint destruction if inadequately treated. Standard care consists primarily of disease-modifying anti-rheumatic drugs (DMARDs), often supported by systemic corticosteroids or intra-articular corticosteroid injections (IACSI). IACSI, despite their use worldwide, show poor response in a substantial group of patients.

View Article and Find Full Text PDF

Primary antiphospholipid syndrome (PAPS) is a systemic autoimmune disease characterized by thrombosis, pregnancy morbidity, and the presence of antiphospholipid antibodies (aPL). Anticoagulants form the mainstay of treatment in PAPS. A growing number of studies suggest a previously underappreciated role of the immune system in the pathophysiology of PAPS.

View Article and Find Full Text PDF

Objective: We aimed to compile evidence for the efficacy and safety of therapeutic options for the peripheral arthritis domain of psoriatic arthritis (PsA) for the revised 2021 Group in Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations.

Methods: A working group consisting of clinicians and patient research partners was convened. We reviewed the evidence from new randomized controlled trials (RCTs) for PsA treatment from February 19, 2013, to August 28, 2020.

View Article and Find Full Text PDF
Article Synopsis
  • The study analyzed the effects of switching adult patients with rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis from the reference drug adalimumab (Humira®) to its biosimilar (Amgevita®).
  • Out of 603 patients, over 93% successfully transitioned without significant changes in disease activity or safety, confirming the equivalence of the two treatments.
  • Some patients experienced nocebo effects, highlighting the importance of addressing patient perceptions to optimize treatment outcomes and maintain cost benefits of using biosimilars.
View Article and Find Full Text PDF